Treatment
Nivolumab clinical trials
We’re tracking 261 recruiting studies that include Nivolumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06064097RecruitingPhase 2
Nivolumab plus chemo for young people with nasopharyngeal cancer
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Birmingham, AlabamaAges Up to 21 years - NCT06053658RecruitingPhase 2
Tivozanib and Nivolumab for advanced kidney cancer
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
Irvine, CaliforniaAges 18 years+ - NCT05901285RecruitingPhase 1
Vaccine injected into tumors plus immunotherapy for advanced cancers
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
Tucson, ArizonaAges 18 years+ - NCT05779423RecruitingPhase 2
Freezing tumor plus two immunotherapies for advanced melanoma
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Boston, MassachusettsAges 18 years+ - NCT05533983Recruiting
Stool transplant plus nivolumab for advanced solid cancers
This study tests whether transferring stool microbiome (“FMT,” stool transplant) along with nivolumab can improve outcomes in people with advanced solid cancers that kept worsening even after anti–PD-1/PD-L1 treatment. It also looks at stool and blood changes to understand why the treatment might work.
SeoulAges 19 years+ - NCT04248569RecruitingPhase 1
Vaccine plus immunotherapy for a specific liver cancer gene change
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
Baltimore, MarylandAges 12 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Birmingham, AlabamaAges 5–60 - NCT05677490RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced stomach or esophagus cancer
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
Birmingham, AlabamaAges 18 years+ - NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Orange, CaliforniaAges 18–90 - NCT05498792RecruitingEarly Phase 1
Trial testing CBL0137 with two immunotherapy drugs for melanoma
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05384496RecruitingPhase 2
Axitinib and nivolumab for advanced mucosal melanoma
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
Harrison, New YorkAges 18 years+ - NCT05187429RecruitingPhase 1/Phase 2
Low-dose nivolumab for adults with HIV on stable therapy
This trial tests whether a low dose of nivolumab can safely affect the immune system in adults living with HIV who are already on stable HIV treatment. You may benefit by helping researchers understand a new approach, but the main goal is to check safety and early effectiveness.
Melbourne, VictoriaAges 18–65 - NCT05272384RecruitingPhase 1
Testing nivolumab plus ASTX727 for hard-to-treat lymphoma
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
Birmingham, AlabamaAges 18 years+ - NCT05257590RecruitingPhase 2
CVM-1118 plus nivolumab for advanced liver cancer
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Kaohsiung CityAges 18 years+ - NCT05234307RecruitingPhase 1
Nivolumab plus PBF-1129 for advanced lung cancer
This Phase 1 trial tests a new combination of PBF-1129 with nivolumab (an immune therapy) for lung cancer that has come back or spread. It aims to find a safe dose and see whether the combination can shrink tumors and improve outcomes.
Columbus, OhioAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT05039073RecruitingPhase 2
Brentuximab plus nivolumab for Hodgkin lymphoma after prior treatment
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
Atlanta, GeorgiaAges 12 years+ - NCT05048212RecruitingPhase 2
Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Houston, TexasAges 18 years+ - NCT04933903RecruitingPhase 2
Neoadjuvant low-dose radiation plus immunotherapy before lung surgery
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
Providence, Rhode IslandAges 18 years+ - NCT04991025RecruitingPhase 2
Adding certolizumab to chemotherapy and nivolumab for lung cancer
This study tests whether adding an extra medication, certolizumab, to the usual chemotherapy and an immunotherapy drug called nivolumab can help people with early-stage lung cancer before they have surgery. It aims to see if this combination shrinks the cancer more and improves outcomes.
Basking Ridge, New JerseyAges 18 years+ - NCT04902443RecruitingPhase 1
Pomalidomide and nivolumab for virus-related cancers
This trial tests two drugs (pomalidomide and nivolumab) in people with cancers caused by viruses. The goal is to see if this combination can shrink or control tumors that haven't responded to standard therapies.
Bethesda, MarylandAges 18–99 - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+
Common questions
- Are there clinical trials studying Nivolumab?
- Yes. Clin2 currently lists 261 recruiting studies that include Nivolumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Nivolumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Nivolumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Nivolumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.